David Aviezer he serves as Associate Professor, adjunct, in the biotechnology program at the Faculty of Life Sciences, Bar-Ilan University. 
Prof. Aviezer has 25 years of experience in biotechnology executive management, advancing biopharmaceutical drugs and treatments from early-stage research up to their approval by FDA and into commercialization. He has hands on experience in creating strategic partnerships and research agreements. David has raised significant capital in the US public markets on Wall Street and from private venture capital funds.  
Currently David serves as Executive Chairman, of Kamari Pharma, a clinical stage private biotechnology company focused on rare skin disorders and abundant dermatology indications. Kamari is backed by prominent VCs such as Pontifax and Arkin. In addition, he is an Advisor to Cytoreason- a digital health company, based on utilizing AI and biological data learning for drug development. Cytoreason recently signed a significant agreement with Pfizer.  David is a member of the Investment committee of the Israeli Innovation Authority for start-up and incubator companies and a member of the 8400 Health Network.                                                                                                                     
Prof. Aviezer served as Chairman of the Board of – Metabomed a clinical stage biotech company developing cancer metabolism drugs. Metabomed investors included several pharma companies such as Pfizer, Merck and Boehringer. David spent 12 years of his career as CEO of Protalix BioTherapeutics Inc. a publicly traded biotechnology company (NYSE: PLX). His Major achievements as CEO include leading the development of a proprietary recombinant therapeutic enzyme for the treatment of Gaucher’s disease. Leading the company from initiation of biochemical, analytical and preclinical animal studies through completion of phase III clinical trials and approval by the FDA and other regulatory agencies. In addition, leading the development and initiation of clinical trials for three other protein drugs currently undergoing advanced clinical development. Financing: Performing Public Offerings on the NY stock exchange for raising significant capital in equity and convertibles and listing Protalix on Wall Street. Raising significant private VC investments from prominent US investors. During David's tenure as CEO, Protalix reached a ~$1 billion market cap. Business Development: Establishing a multimillion-dollar strategic agreement with Pfizer. Signing strategic R&D collaboration agreements with pharmaceutical companies, governments and scientific and medical institutions. Operations: Forming a team from incubation and managing a staff of 250 scientists and biotech engineers. Building a state-of-the-art FDA & EMA approved GMP manufacturing facility. Prior to that he was General Manager of ProChon Biotech / Cell Transplantation Innovations, a company focused on skeletal and orthopedic disorders, leading its autologous cartilage cell-based therapy for treating knee cartilage defects, to regulatory approval in Israel. Before that, he was a Visiting Scientist at the Medical Research Division of Cyanamid – Wyeth (now Pfizer) in Pearl River, New York. Focusing on cancer research and angiogenesis. 
David has presented extensively in global scientific, biotechnology, medical and life science investor conferences. He published ~30 peer reviewed scientific papers and has won several awards and scholarships.  
He holds a Ph.D. in Molecular Biology and Biochemistry from the Weizmann Institute of Science, Israel and an M.B.A. from Bar-Ilan University, Business School. Ramat Gan, Israel.